ARCHIVES

Wyden Compared Taxol To AZT; But Experts Note Lack Of Patent

This article is from The Cancer Letter archive.

Vol. 17 No. 32 | August 9, 1991

Download PDF Visit The Full Archive

Related Articles

Lung Cancer Gets Less Press, Study Finds

May 18, 2001

Biotherapeutics Reports LAK/IL-2 Toxicity Reduced With Constant Infusion Of IL-2

April 17, 1987

NCI Plans Phase-Out Of K04 Career Awards

March 3, 1995

ACCC Members Hear How Community Cancer Programs Are Developed

February 11, 1977

Roanoke Awarded CHOP Contract

May 29, 1981

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

May 28, 2004